Crohn's disease
ICD-10 K50 · ICD-11 DD70

What Is the First-Line Treatment for Moderate-to-Severely Active Crohn's Disease?

For adult outpatients presenting with moderate-to-severely active Crohn's disease, current evidence supports an upfront advanced therapy strategy as the preferred initial approach — rather than beginning with conventional step-up options.

Clinical Scenario

Moderate-to-severely active Crohn's disease in the adult ambulatory setting. The choice of initial treatment strategy at this stage directly influences the likelihood of achieving and sustaining remission.

Treatment Approach

Upfront use of an advanced therapy — biological or small-molecule — is favoured over initiating with corticosteroids and/or immunomodulator monotherapy. Multiple agent options are supported, with varying strengths of recommendation across agent classes. The full selection criteria, combination considerations, and sequencing algorithm are detailed in the complete protocol.

Clinical Goals

The primary patient-centric outcomes are induction and maintenance of clinical remission, defined as a Crohn's Disease Activity Index (CDAI) below 150.

Instant Access to Structured Evidence-Based Regimens

References

  1. In adult outpatients with moderate-to-severely active CD, the AGA recommends the use of infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, or upadacitinib, over no treatment.
  2. In adult outpatients with moderate-to-severely active CD, the AGA suggests the use of certolizumab pegol or vedolizumab, over no treatment.
  3. In adult outpatients with moderate-to-severely active CD, the AGA SUGGESTS upfront use of advanced therapy compared with step-up therapy with initial use of corticosteroids and/or immunomodulator monotherapy.
  4. In individuals with moderate-to-severely active CD in the ambulatory setting, induction and maintenance of clinical remission were considered critical, patient-centric outcomes for decision making.
  5. CDAI scores <150 suggest clinical remission, and scores 150–220, 221–450, and >450 denote mild, moderate, and severe disease, respectively.
View source ↗